Like most websites The Translational Scientist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Research Field Neuroscience

Untangling Tau

Alzheimer’s disease is a truly dreadful illness, but on a scientific level it is a fascinating one. The whole field of behavioral neurology – studying brain–behavior relationships – has learnt a great deal from these patients. Specifically, the way that people lose function during the course of the disease has taught us much about how the brain works, and raised many intriguing questions (many of which remain unanswered). An Alzheimer’s patient can remember in crystal-clear detail something that happened a decade ago, but can be completely unable to recall what happened three minutes ago. Patients often lose very specific aspects of cognitive function (for example, their ability to do sums or understand language) while seemingly more complex faculties remain entirely intact. We are now starting to understand exactly why and how this happens.

The past decade has seen an extraordinary series of breakthroughs. We have mapped at least a dozen genes that clearly impact the relative risk of Alzheimer’s disease, although we understand the mechanisms of action of just three of them. When I started out as a neurologist, we could only diagnose Alzheimer’s disease post mortem. Now we can use spinal taps to test for biomarkers or PET scans to look directly at the brain, and diagnose patients while they are alive. We have a much better handle on the biochemistry and molecular biology of the lesions visible in the brain, and we now know that there is more to the story than what we can see through the microscope. We have also come to appreciate just how long the pre-symptomatic phase of the disease is – around 15 years.

There is a mountain to climb – but it is not insurmountable. We recently made a discovery that may shed light on how the disease progresses at a molecular level.

Read the full article now

Log in or register to read this article in full and gain access to The Translational Scientist’s entire content archive. It’s FREE!


Or register now - it’s free!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

When you click “Register” we will email you a link, which you must click to verify the email address above and activate your account. If you do not receive this email, please contact us at [email protected].

About the Author

Bradley Hyman

Bradley Hyman is Director, Massachusetts Alzheimer’s Disease Research Center & Co-Director, MGH Memory Disorders Unit & John B. Penney Jr. Professor of Neurology, Harvard Medical School, USA.

Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts